Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer

Oncotarget

Volumn 7, Issue 38, 2016, Pages 61575-61586

  van Ginkel, Joost H ^a   de Leng, Wendy W J ^a   de Bree, Remco ^a   van Es, Robert J J ^a   Willems, Stefan M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Diagnostic biomarkers; Head and neck cancer; Mutations; Next generation sequencing; TP53

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; CDK4 PROTEIN, HUMAN; CDKN2A PROTEIN, HUMAN; CIRCULATING TUMOR DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2C; F BOX/WD REPEAT CONTAINING PROTEIN 7; FBXW7 PROTEIN, HUMAN; HRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; RB1 PROTEIN, HUMAN; RETINOBLASTOMA BINDING PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CDK4 GENE; CDKN2A GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DISTANT METASTASIS; FBXW7 GENE; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NEXT GENERATION SEQUENCING; ONCOGENE H RAS; PIK3CA GENE; PREVALENCE; RB1 GENE; RETROSPECTIVE STUDY; SMOKING; TP53 GENE; BLOOD; BONE TUMOR; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; GENETICS; HEAD AND NECK TUMOR; HIGH THROUGHPUT SEQUENCING; LIQUID BIOPSY; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; SECONDARY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CIRCULATING TUMOR DNA; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DNA MUTATIONAL ANALYSIS; F-BOX-WD REPEAT-CONTAINING PROTEIN 7; FEMALE; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIQUID BIOPSY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA BINDING PROTEINS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84991783900     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11196     Document Type: Article

References (59)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015; 136:E359-386.
2. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333:1154-1157.
3. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333:1157-1160.
4. Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Annals of oncology. 2015; 26:1216-1223.
5. Comprehensive genomic characterization of head neck squamous cell carcinomas. Nature. 2015; 517:576-582.
6. Marur S, D'Souza G, Westra WH, Forastiere AA. HPVassociated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology. 2010; 11:781-789.
7. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. The New England journal of medicine. 2010; 363:24-35.
8. Braakhuis BJ, Leemans CR, Visser O. Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011. Oral oncology. 2014; 50:670-675.
9. Chung CH, Parker JS, Ely K, Carter J, Yi YJ, Murphy BA, Ang KM, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, Yarbrough WG. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappa B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer research. 2006; 66:8210-8218.
10. Chung CH, Parker JS, Karaca G, Wu JY, Funkhouser WK, Moore' D, Butterfoss D, Xiang D, Zonation A, Yin XY, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG, Perou CM. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004; 5:489-500.
11. Graveland AP, Braakhuis BJ, Eerenstein SE, de Bree R, Bloemena E, de Maaker M, van den Brekel MW, Dijk F, Mesker WE, Tanke HJ, Leemans CR, Brakenhoff RH. Molecular diagnosis of minimal residual disease in head and neck cancer patients. Cell Oncol (Dordr). 2012; 35:367-375.
12. Smeets SJ, Brakenhoff RH, Ylstra B, van Wieringen WN, van de Wiel MA, Leemans CR, Braakhuis BJ. Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cellular oncology. 2009; 31:291-300.
13. Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG. Decision making in the management of recurrent head and neck cancer. Head & neck. 2014; 36:144-151.
14. Leemans CR, Tiwari R, Nauta JJP, Vanderwaal I, Snow GB. Recurrence at the Primary Site in Head and Neck-Cancer and the Significance of Neck Lymph-Node Metastases as a Prognostic Factor. Cancer. 1994; 73:187-190.
15. Graveland AP, Golusinski PJ, Buijze M, Douma R, Sons N, Kuik DJ, Bloemena E, Leemans CR, Brakenhoff RH, Braakhuis BJM. Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. International Journal of Cancer. 2011; 128:1852-1859.
16. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nature reviews Cancer. 2011; 11:9-22.
17. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, Print C. Predictive and prognostic molecular markers for cancer medicine. Therapeutic advances in medical oncology. 2010; 2:125-148.
18. Noorlag R, van Kempen PM, Stegeman I, Koole R, van Es RJ, Willems SM. The diagnostic value of 11q13 amplification and protein expression in the detection of nodal metastasis from oral squamous cell carcinoma: a systematic review and meta-analysis. Virchows Archiv. 2015; 466:363-373.
19. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nature reviews Clinical oncology. 2015; 12:11-26.
20. Thariat J, Vignot S, Lapierre A, Falk AT, Guigay J, Van Obberghen-Schilling E, Milano G. Integrating genomics in head and neck cancer treatment: Promises and pitfalls. Crit Rev Oncol Hematol. 2015; 95:397-406.
21. Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, Schuhmann A, Bosch FX. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer research. 1993; 53:4189-4196.
22. Califano J, vanderRiet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer research. 1996; 56:2488-2492.
23. Gollin SM. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head & neck. 2001; 23:238-253.
24. Braakhuis BJ, Leemans CR, Brakenhoff RH. A genetic progression model of oral cancer: current evidence and clinical implications. Journal of oral pathology & medicine. 2004; 33:317-322.
25. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer research. 1993; 53:4477-4480.
26. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953; 6:963-968.
27. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer research. 2003; 63:1727-1730.
28. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010; 38:6159-6175.
29. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA. Circulating mutant DNA to assess tumor dynamics. Nature Medicine. 2008; 14:985-990.
30. Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JHJ, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6:42008-42018. doi: 10.18632/oncotarget.5788.
31. Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Research. 2014; 16.
32. de Bree R, van der Putten L, Brouwer J, Castelijns JA, Hoekstra OS, Leemans CR. Detection of locoregional recurrent head and neck cancer after (chemo) radiotherapy using modern imaging. Oral oncology. 2009; 45:386-393.
33. Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, Menander KA, Licato LL, Chada S, Gibbons RD, Olivier M, Hainaut P, et al. Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. Clinical cancer research. 2009; 15:7719-7725.
34. Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Human genetics. 2015; 134:497-507.
35. van Houten VMM, Tabor MP, van den Brekel MWM, Kummer JA, Denkers F, Dijkstra J, Leemans R, van der Waal I, Snow GB, Brakenhoff RH. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. Journal of Pathology. 2002; 198:476-486.
36. Wang X, Chen S, Chen X, Zhang C, Liang X. Tumorrelated markers in histologically normal margins correlate with locally recurrent oral squamous cell carcinoma: a retrospective study. Journal of oral pathology & medicine. 2016; 45:83-88.
37. Poeta ML, Manola J, Goldenberg D, Forastiere A, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM. The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clinical cancer research. 2009; 15:7658-7665.
38. Lopez M, Aguirre JM, Cuevas N, Anzola M, Videgain J, Aguirregaviria J, Castro A, de Pancorbo MM. Use of cytological specimens for p53 gene alteration detection in oral squamous cell carcinoma risk patients. Clin Oncol (R Coll Radiol). 2004; 16:366-370.
39. Mountzios G, Rampias T, Psyrri A. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Annals of oncology. 2014; 25:1889-1900.
40. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. The New England journal of medicine. 2007; 357:2552-2561.
41. Seiwert TY, Zuo ZX, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Bragelmann J, DeBoer R, Weichselbaum RR, Langerman A, et al. Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research. 2015; 21:632-641.
42. Pickering CR, Zhang JX, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Alves MVO, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JPJ, Zweidler-McKay PA, et al. Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers. Cancer discovery. 2013; 3:770-781.
43. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nature communications. 2013; 4:2873.
44. Noorlag R, van Kempen PMW, Moelans CB, de Jong R, Blok LER, Koole R, Grolman W, van Diest PJ, van Es RJJ, Willems SM. Promoter hypermethylation using 24-gene array in early head and neck cancer Better outcome in oral than in oropharyngeal cancer. Epigenetics. 2014; 9:1220-1227.
45. van Kempen PM, Noorlag R, Braunius WW, Moelans CB, Rifi W, Savola S, Koole R, Grolman W, van Es RJ, Willems SM. Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. Cancer medicine. 2015; 4:1525-1535.
46. Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, et al. Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics. 2014; 9:1031-1046.
47. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. International journal of oncology. 2008; 32:101-111.
48. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer discovery. 2013; 3:761-769.
49. William WN, Jr., El-Naggar AK. A novel target for oral cancer chemoprevention? Notch quite, yet. Cancer Prev Res (Phila). 2015; 8:262-265.
50. Izumchenko E, Sun K, Jones S, Brait M, Agrawal N, Koch W, McCord CL, Riley DR, Angiuoli SV, Velculescu VE, Jiang WW, Sidransky D. Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila). 2015; 8:277-286.
51. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine. 2012; 366:883-892.
52. Jacoby MA, Duncavage EJ, Walter MJ. Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing. Trends in Cancer. 2016; 1:10.
53. Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. The Journal of clinical investigation. 2016; 126:169-180.
54. Korc M. Smad4: gatekeeper gene in head and neck squamous cell carcinoma. The Journal of clinical investigation. 2009; 119:3208-3211.
55. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. The American journal of pathology. 2002; 161:1961-1971.
56. de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E, van Lieshout S, Loberg RD, de Jonge M, Voest EE, de Weger RA, Steeghs N, Langenberg MH, Sleijfer S, Willems SM, et al. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material. PloS one. 2016; 11:e0149405.
57. Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med. 2015; 7:80.
58. van Kempen PM, Verdam FJ, de Poel E, Braunius WW, de Weger RA, van Es RJ, Grolman W, Willems SM. TP53 Y220C Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma. Pathobiology: journal of immunopathology, molecular and cellular biology. 2015; 82:21-27.
59. Hoogstraat M, Hinrichs JW, Besselink NJ, Radersma-van Loon JH, de Voijs CM, Peeters T, Nijman IJ, de Weger RA, Voest EE, Willems SM, Cuppen E, Koudijs MJ. Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology. The Journal of molecular diagnostics: JMD. 2015; 17:10-18.